NKTX实时信号 | 通过Getagraph.com最大化利润

购买 107703 min ago

@ $10.55

发出时间: 14 Feb 2024 @ 23:41

回报率: -34.85%

上一信号: Feb 14 - 22:30

上一信号: 出售

回报率: -3.61 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	978 376
平均成交量	1.02M
市值	484.11M
EPS	$0 ( 2024-03-21 )
下一个收益日期	( $-0.550 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.86
ATR14	$0.0120 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-27	Ra Capital Management, L.p.	Buy	3 000 000	Common Stock
2024-03-27	Ra Capital Management, L.p.	Buy	3 000 031	Pre- Funded Warrants (Right to Buy)
2024-03-27	George Simeon	Buy	1 548 341	Common Stock
2024-03-27	George Simeon	Buy	451 659	Common Stock
2024-03-01	Hastings Paul J	Sell	12 358	Common Stock

INSIDER POWER
95.72
Last 99 transactions
Buy: 11 537 422 \| Sell: 349 926

音量相关性

長: -0.06 (neutral)

短: 0.66 (moderate)

Signal:(64.2) Neutral

Nkarta, Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Nkarta, Inc. 相关性 - 货币/商品

0.02
( neutral )

0.34
( neutral )

0.00
( neutral )

0.04
( neutral )

0.84
( strong )

0.46
( neutral )

Nkarta, Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$-5.87M (0.00 %)
EPS:	$-2.40

FY	2023
营收:	$0
毛利润:	$-5.87M (0.00 %)
EPS:	$-2.40

FY	2022
营收:	$0
毛利润:	$-6.57M (0.00 %)
EPS:	$-2.74

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-2.62

Financial Reports:

No articles found.

Nkarta, Inc.

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.